Od-Neb Pregnancy

• Pregnancy of Od-Neb in details
• Od-Neb breastfeeding
• Od-Neb reviews

Pregnancy of Od-Neb in details

Outcome information following maternal use of Od-Neb in pregnancy is limited (Sullo 2015).

Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, fetal growth should be monitored during pregnancy and the newborn should be monitored for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).

Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 203 2019).

When treatment of chronic hypertension in pregnancy is indicated, agents other than Od-Neb are preferred (ACOG 203 2013; ESC [Regitz-Zagrosek 2018]; Magee 2014). Females with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]).

Od-Neb breastfeeding

Use not recommended Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: Breastfed infants should be monitored for the signs and symptoms of beta blockade, for example, bradycardia, respiratory distress, and hypoglycemia.

Beta-adrenergic blocking agents, particularly lipophilic agents like this drug, have caused adverse events in breastfed newborns. In animal models, this drug is excreted into breastmilk and is expected to have moderate accumulation in the infant due to its high protein binding and long half-life.

See references

References for pregnancy information

1. "Product Information. Bystolic (Od-Neb)." Forest Pharmaceuticals, St. Louis, MO.
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
4. "Product Information. Bystolic (Od-Neb)." Forest Pharmaceuticals, St. Louis, MO.

References

1. PubMed Health. "Nebivolol (By mouth): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
2. Human Metabolome Database (HMDB). "Nebivolol: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).
3. LiverTox. "Nebivolol: LIVERTOX provides up-to-date, accurate, and easily accessed information on the diagnosis, cause, frequency, patterns, and management of liver injury attributable to prescription and nonprescription medications, herbals and dietary supplements. ". https://livertox.nlm.nih.gov//Nebivo... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology